March 29, 2012
XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY), a biopharmaceutical development company, today reported its results for the fourth quarter and year ended
December 31, 2011
, CEO of XTL, stated, "2011 was a very significant year for XTL and we are very proud of our achievements in expanding our drug development pipeline with SAM-101 for the treatment of schizophrenia. SAM-101 is combination therapy of anti-psychotic existing drugs with minocycline. We now have a worldwide exclusive license for the development and commercialization of SAM-101 for the treatment of psychotic disorders. We in-licensed SAM-101 after it successfully completed a phase 2a prospective, randomized, double-blind, placebo-controlled clinical trial conducted on about 70 schizophrenics in
. The trial met its endpoints showing that SAM-101 improves the positive symptoms of the disease as well as the patients' cognitive state, minimizes the negative symptoms (social parameters and patient cognition) and reduces weight-gain side effects among patients".
"In the past year we were granted an orphan drug designation from the FDA for our rHuEPO for the treatment of multiple myeloma. The designation can provide us with significant regulatory and financial advantages to rapidly move our candidate forward in clinical trials. Upon the FDA's marketing approval for rHuEPO for the treatment of multiple myeloma we will be entitled to marketing exclusivity for seven years in the US. In addition, the benefits include among others tax incentives, exemption of FDA filing fees and clinical research financial subsidization". Mr. Grossman added, "Since the 4
quarter of 2011, we are conducting a research which includes collection of data relating to the level of specific proteins in the blood of a group of patients with multiple myeloma with rHuEPO as part of the preparations for our phase 2 rHuEPO clinical trial."
December 31, 2011
we had cash and cash equivalents of
, we successfully completed a financing in
by way of private placement which also included an exercise of warrants, led by institutional investors. Such funds will enable us to finance our activities through at least into 2014 and support the acceleration of our drug development programs. Our strategy to continually identify and acquire new technologies remains and we are very keen in this front," stated Mr. Grossman.
, we also enhanced our capabilities of collecting clinical data by signing a strategic collaboration agreement with the research institute of Clalit Health Services,
largest HMO. This agreement enables us to define clinical outcomes that we seek from Clalit's clinical database for the benefit of focusing our clinical trials design."
About XTL Biopharmaceuticals, Ltd
XTL Biopharmaceuticals, Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. The Company is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C.